| Identification | Back Directory | [Name]
Xaliproden hydrochloride | [CAS]
90494-79-4 | [Synonyms]
SR 57746A
XALIPRODEN HYDROCHLORIDE
WVHBEIJGAINUBW-UHFFFAOYSA-N
Xaliproden hydrochloride NEW
1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine,hydrochloride
1,2,3,6-TETRAHYDRO-1-[2-(2-NAPHTHALENYL)ETHYL]-4-[3-(TRIFLUOROMETHYL)PHENYL]-PYRIDINE HYDROCHLORIDE
SR-57746A, 1,2,3,6-Tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine hydrochloride | [Molecular Formula]
C24H23ClF3N | [MDL Number]
MFCD00896209 | [MOL File]
90494-79-4.mol | [Molecular Weight]
417.894 |
| Hazard Information | Back Directory | [Originator]
Xaliproden
hydrochloride,Sanofi (Sanofi-
Aventis) | [Uses]
Xaliproden is a 5-HT1A agonist used in the treatment of allodynia. | [Definition]
ChEBI: Xaliproden hydrochloride is a member of naphthalenes. | [Manufacturing Process]
A solution of 27.8 kg of 2-naphthylacetic acid in 95 L of tetrahydrofuran is
added, at a temperature below 20°C to a mixture of 27.5 L of tetrahydrofuran
and 10.0 kg of lithium aluminum hydride. The mixture is cooled to 0°C and
the following are then added slowly: firstly 10 L of water, then a solution of
1.5 kg of sodium hydroxide in 10 L of water, and finally 30 L of water. The
salts which separate out are washed with 160 L of tetrahydrofuran and then filtered off. The combined tetrahydrofuran solutions are evaporated and the
24.5 kg of 2-(2-naphthyl)ethanol are obtained.
The 2-(2-naphthyl)ethanol is treated with 138 L of concentrated hydrobromic
acid. The mixture is refluxed for 5 h and allowed to return to room
temperature, with stirring, and the product obtained is then filtered off and
washed with water. The moist product is dissolved in 147 L of isopropanol
under reflux, about 75 L of solvent are removed by distillation and the
mixture is allowed to cool overnight. The product which has crystallized is
filtered off, washed with previously cooled isopropanol and dried under
vacuum at 40°C. So the 2-(2-bromoethyl)naphthalene is obtained (yield:
81%, calculated relative to the starting naphthylacetic acid).
A mixture of 12.5 g of 2-(2-bromoethyl)naphthalene, 14.0 g of 4-(3-
trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride, 4.34 g of
sodium hydroxide, 135 ml of water and 95 ml of 95% ethanol is refluxed for 5
h, the reaction mixture is subsequently allowed to cool to room temperature
overnight and then filtered and the product isolated in this way is washed with
water and dried under vacuum at 50°C to give 1-[2-(2-naphthyl)ethyl]-4-(3-
trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine (yield of 90%, calculated
relative to the starting 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine
hydrochloride). | [Therapeutic Function]
Serotonin antagonist, Nootropic | [Biological Activity]
Orally active, full agonist at 5-HT 1A receptors. Binds rat 5-HT 1A with high affinity (K i = 2.0 nM) and is > 300-fold selective over other 5-HT receptor subtypes (IC 50 > 650 nM). Increases motoneuron survival and promotes effects of NGF on neurite outgrowth in vitro . Displays neurotrophic activity in several neurodegenerative models in vivo . |
|
|